Currently, there are 32.13M common shares owned by the public and among those 20.29M shares have been available to trade.
The company’s stock has a 5-day price change of 31.32% and -7.28% over the past three months. CADL shares are trading 359.18% year to date (YTD), with the 12-month market performance up to 467.23% higher. It has a 12-month low price of $1.02 and touched a high of $14.60 over the same period. CADL has an average intraday trading volume of 2.42 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 32.97%, 26.17%, and 13.50% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Candel Therapeutics Inc (NASDAQ: CADL) shares accounts for 14.78% of the company’s 32.13M shares outstanding.
It has a market capitalization of $150.99M and a beta (3y monthly) value of -1.00. The earnings-per-share (ttm) stands at -$1.74. Price movements for the stock have been influenced by the stock’s volatility, which stands at 42.85% over the week and 19.32% over the month.
Earnings per share for the fiscal year are expected to decrease by -25.95%, and 109.09% over the next financial year.
Looking at the support for the CADL, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on December 02, 2022, with the firm’s price target at $11. BMO Capital Markets coverage for the Candel Therapeutics Inc (CADL) stock in a research note released on November 19, 2021 offered a Outperform rating with a price target of $18. UBS was of a view on August 23, 2021 that the stock is Buy, while Jefferies gave the stock Buy rating on August 23, 2021, issuing a price target of $22. Credit Suisse on their part issued Outperform rating on August 23, 2021.
